Multicentric Trial of the Treatment of Huntington's Disease by Cysteamine (RP103)
Phase of Trial: Phase II/III
Latest Information Update: 10 Dec 2015
At a glance
- Drugs Mercaptamine bitartrate (Primary)
- Indications Huntington's disease
- Focus Registrational; Therapeutic Use
- Acronyms CYST-HD
- 10 Dec 2015 Results of 36-month efficacy published in a Raptor Pharmaceuticals media release.
- 06 Aug 2015 According to a Raptor media release, 36-month data from this study is expected to be reported in the fourth quarter of 2015.
- 07 May 2015 According to a Raptor media release, 36-month data from this study is expected in second-half of 2015.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History